BRKR vs. BIO, AVTR, TXG, WAT, QTRX, PACB, AXDX, MTD, SNX, and EPAM
Should you be buying Bruker stock or one of its competitors? The main competitors of Bruker include Bio-Rad Laboratories (BIO), Avantor (AVTR), 10x Genomics (TXG), Waters (WAT), Quanterix (QTRX), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Mettler-Toledo International (MTD), TD SYNNEX (SNX), and EPAM Systems (EPAM).
Bio-Rad Laboratories (NYSE:BIO) and Bruker (NASDAQ:BRKR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.
Bruker received 304 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 64.91% of users gave Bruker an outperform vote while only 64.87% of users gave Bio-Rad Laboratories an outperform vote.
Bruker has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bruker had 7 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 14 mentions for Bruker and 7 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.70 beat Bruker's score of 0.54 indicating that Bruker is being referred to more favorably in the news media.
65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 79.5% of Bruker shares are held by institutional investors. 17.1% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 28.3% of Bruker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Bio-Rad Laboratories has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Bruker has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.
Bio-Rad Laboratories presently has a consensus target price of $461.00, suggesting a potential upside of 56.88%. Bruker has a consensus target price of $84.86, suggesting a potential upside of 13.04%. Given Bruker's stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bruker.
Bruker has a net margin of 13.38% compared to Bruker's net margin of -12.37%. Bio-Rad Laboratories' return on equity of 27.31% beat Bruker's return on equity.
Summary
Bruker beats Bio-Rad Laboratories on 15 of the 17 factors compared between the two stocks.
Get Bruker News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRKR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
